STOCK TITAN

Palatin Technologies, Inc. - $PTN STOCK NEWS

Welcome to our dedicated page for Palatin Technologies news (Ticker: $PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Technologies stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Palatin Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Palatin Technologies's position in the market.

Rhea-AI Summary
Palatin Technologies plans to initiate a clinical study of its melanocortin 4 receptor (MC4R) agonist, bremelanotide, in combination with a Glucagon Like Peptide-1 (GLP-1) agonist for treating obesity. Preclinical data and prior clinical studies support the potential of Palatin's melanocortin agonists for weight loss. The combination therapy aims to improve treatment adherence and promote long-term weight loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
-
Rhea-AI Summary
Palatin Technologies presents data on the impact of PL8177 in treating inflammatory diseases at UEG Week 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
Rhea-AI Summary
Palatin to Deliver Plan of Compliance to NYSE American
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease is complete with 570 patients enrolled. Interim analysis of initial 120 patients showed statistical separation for clinical efficacy across multiple signs and symptoms of Dry Eye. Vyleesi net product revenue increased 47% over the prior quarter. Prescriptions dispensed increased 16% over the prior quarter. Palatin's cash, cash equivalents, and marketable securities were approximately $11.0 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
-
Rhea-AI Summary
Palatin Technologies, Inc. will announce its Q4 & FY 2023 operating results on September 28, 2023. Conference call and webcast to provide updates on programs under development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Palatin Technologies to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
conferences
Rhea-AI Summary
Palatin Technologies, Inc. completes enrollment of 570 patients in the PL9643 MELODY-1 Phase 3 study for dry eye disease (DED). Topline data expected by late 4Q 2023. Interim analysis of first 120 patients shows excellent safety and tolerability. PL9643 has potential to address multiple signs and symptoms of DED.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
Palatin Technologies, Inc. (PTN) has initiated a clinical development program for bremelanotide, a melanocortin receptor 4 (MCR4) agonist, co-formulated with a PDE5 inhibitor (PDE5i), for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy. The company aims to address the unmet medical needs of the 30%-40% of ED patients who do not respond to current PDE5i treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
none
-
Rhea-AI Summary
Palatin Technologies announces first sale of Vyleesi in China and completion of Phase 3 trial in South Korea for HSDD treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
Rhea-AI Summary
Palatin Technologies enters strategic partnership with UpScriptHealth to increase access to Vyleesi for patients with hypoactive sexual desire disorder (HSDD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.86%
Tags
partnership
Palatin Technologies, Inc.

NYSE:PTN

PTN Rankings

PTN Stock Data

30.82M
15.54M
3.35%
10.72%
9.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CRANBURY

About PTN

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy